This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooney, K. A. Articles by Wojno, K. J. Search for Related Content PubMed PubMed Citation Articles by Cooney, K. A. Articles by Wojno, K. J.

Identification and Characterization of Proximal 6q Deletions in Prostate Cancer¹

Departments of Internal Medicine [K. A. C., J. C. W.], Surgery [K. A. C., K. J. W.], and Pathology [C. M. C., K. J. W.] and the Michigan Prostate Institute [K. A. C., K. J. W.], University of Michigan Medical School, Ann Arbor, Michigan 48109

Allelic loss of 8p, 10q, 13q, 16q, and 18q has been frequently demonstrated in prostate cancer, implying the existence of putative tumor suppressor genes in these regions. However, there are likely a number of additional genetic events that define the progression from normal prostatic epithelium to prostate cancer that have yet to be identified. To characterize a novel region of deletion in sporadic prostate cancers, 52 tumors obtained from radical prostatectomy cases were analyzed for loss of heterozygosity (LOH) using 10 polymorphic markers spanning chromosome 6 including one marker on 6p and nine markers on 6q. Markers were selected from available databases, and a comprehensive linkage map was constructed. By this analysis, LOH for one or more polymorphic markers was detected in 17 of 52 sporadic prostate cancer cases (33%). Thirteen of 17 tumors were shown to have a common region of allelic loss extending from D6S286 to D6S283 or 6q14–21, with a minimum region of loss containing markers D6S1082 and D6S501. A second separate region of deletion centered around marker D6S404. LOH of one or more 6q markers did not correlate with Gleason grade or pathological stage of the cancer. In summary, this is the first comprehensive analysis of 6q deletions in prostate cancer, and we conclude that 6q14–21 may harbor a tumor suppressor gene important in prostate carcinogenesis.

¹ This work was supported by SPORE Grant P50 CA69568.

² To whom requests for reprints should be addressed, at 5510 MSRB I, 1150 West Medical Center Drive, University of Michigan Medical School, Ann Arbor, MI 48109-0680. Phone: (313) 747-3421; Fax: (313) 763-4151.

Received 7/12/96. Accepted 7/31/96.

This article has been cited by other articles:

				E. Sunami, M. Shinozaki, C. S. Higano, R. Wollman, T. B. Dorff, S. J. Tucker, S. R. Martinez, F. R. Singer, and D. S.B. Hoon Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients Clin. Chem., March 1, 2009; 55(3): 559 - 567. [Abstract] [Full Text] [PDF]

				S. Akakura, C. Huang, P. J. Nelson, B. Foster, and I. H. Gelman Loss of the ssecks/gravin/akap12 Gene Results in Prostatic Hyperplasia Cancer Res., July 1, 2008; 68(13): 5096 - 5103. [Abstract] [Full Text] [PDF]

				W. Liu, B.-L. Chang, S. Cramer, P. P. Koty, T. Li, J. Sun, A. R. Turner, C. Von Kap-Herr, P. Bobby, J. Rao, et al. Deletion of a Small Consensus Region at 6q15, Including the MAP3K7 Gene, Is Significantly Associated with High-Grade Prostate Cancers Clin. Cancer Res., September 1, 2007; 13(17): 5028 - 5033. [Abstract] [Full Text] [PDF]

				P. B. Sinclair, A. Sorour, M. Martineau, C. J. Harrison, W. A. Mitchell, E. O'Neill, and L. Foroni A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia: Identification and Analysis of a Candidate Tumor Suppressor Gene Cancer Res., June 15, 2004; 64(12): 4089 - 4098. [Abstract] [Full Text] [PDF]

				M. Nakamura, M. Kishi, T. Sakaki, H. Hashimoto, H. Nakase, K. Shimada, E. Ishida, and N. Konishi Novel Tumor Suppressor Loci on 6q22-23 in Primary Central Nervous System Lymphomas Cancer Res., February 15, 2003; 63(4): 737 - 741. [Abstract] [Full Text] [PDF]

				Y.-Q. Wu, H. Chen, M. A. Rubin, K. J. Wojno, and K. A. Cooney Loss of Heterozygosity of the Putative Prostate Cancer Susceptibility Gene HPC2/ELAC2 Is Uncommon in Sporadic and Familial Prostate Cancer Cancer Res., December 1, 2001; 61(24): 8651 - 8653. [Abstract] [Full Text] [PDF]

				W. Xia, P. Unger, L. Miller, J. Nelson, and I. H. Gelman The Src-suppressed C Kinase Substrate, SSeCKS, Is a Potential Metastasis Inhibitor in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5644 - 5651. [Abstract] [Full Text] [PDF]

				J. C. Alers, P.-J. Krijtenburg, A. N. Vis, R. F. Hoedemaeker, M. F. Wildhagen, W. C. J. Hop, T. H. van der Kwast, F. H. Schroder, H. J. Tanke, and H. van Dekken Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features Am. J. Pathol., February 1, 2001; 158(2): 399 - 406. [Abstract] [Full Text] [PDF]

				G. An, A. Y. Ng, C. S. R. Meka, G. Luo, S. P. Bright, L. Cazares, G. L. Wright Jr., and R. W. Veltri Cloning and Characterization of UROC28, a Novel Gene Overexpressed in Prostate, Breast, and Bladder Cancers Cancer Res., December 1, 2000; 60(24): 7014 - 7020. [Abstract] [Full Text]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				J. Richter, U. Wagner, P. Schraml, R. Maurer, G. Alund, H. Knonagel, H. Moch, M. J. Mihatsch, T. C. Gasser, and G. Sauter Chromosomal Imbalances Are Associated with a High Risk of Progression in Early Invasive (pT1) Urinary Bladder Cancer Cancer Res., November 1, 1999; 59(22): 5687 - 5691. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]